Latest news with #nutraceuticals
Yahoo
08-07-2025
- Health
- Yahoo
UAE Approves BioAro's Longevity+ Supplement, Signaling Major Market Potential in Global Preventive Health
With a patent-pending formula and international expansion underway, BioAro positions itself as a front-runner in the multi-billion-dollar longevity and wellness sector bottle Woman holding a longevity+ supplement bottle Family photo CALGARY, Alberta, July 08, 2025 (GLOBE NEWSWIRE) -- In a significant move that bridges biotechnology, preventive health, and global wellness trends, Canadian biotech company BioAro has announced the launch of its first nutraceutical product under its new supplement line: Longevity+™, a patent-pending, scientifically formulated capsule designed to support healthy aging through synergistic multi-molecule integration. With approvals already secured in the United Arab Emirates (UAE), BioAro is now poised for expansion into North America, Europe, the UK, and beyond. The launch of Longevity+™ comes at a pivotal time, as the global longevity and healthy aging market is projected to surpass $44 billion by 2030, driven by growing demand for advanced nutraceuticals that go beyond basic supplementation. BioAro's entry into this space is far from ordinary. It brings together cutting-edge research, clinical insight, and multi-omics intelligence—hallmarks of its biotech origins—to deliver a product rooted in science, not hype. A Breakthrough, All-in-One Longevity Protocol What sets Longevity+™ apart is not just its formulation, but its philosophy: simplicity meets synergy. Each daily dose (two capsules) contains a potent blend of Nicotinamide Mononucleotide (NMN), Resveratrol, Coenzyme Q10, Curcumin, Vitamin D, and Vitamin B12—molecules that individually support cellular energy, mitochondrial health, inflammation modulation, and cognitive clarity. But when taken together in a precisely engineered ratio, early scientific research suggest they may create synergistic effects that amplify their individual benefits—potentially offering an integrated path to extending healthspan. "We didn't want to be just another supplement company," says Dr. Anmol Kapoor, Founder of BioAro. "Our formulation was born from years of precision health research in genomics, metabolomics, and personalized medicine. We've built Longevity+ from a systems biology perspective, focusing on how molecules interact—not just how they function alone." From Lab to Life: A Canadian Biotech's Global Ambition Rooted in BioAro's legacy of precision diagnostics and AI-driven multi-omics, the supplement line represents the company's first consumer-facing health supplement product, translating years of complex research into a simple, daily protocol. With regulatory clearance and market entry approval in the UAE, one of the world's most progressive markets for health and wellness innovation, BioAro is finalizing distribution partnerships across North America, Europe, the UK, India, and Southeast Asia. The company also plans to integrate Longevity+ into its clinical longevity programs, including personalized health assessments and digital wellness tracking, forming an end-to-end ecosystem for those seeking to proactively manage aging and vitality. What's Inside Matters NMN (Nicotinamide Mononucleotide): A powerful NAD+ precursor, vital for mitochondrial health and cellular repair. Resveratrol: A polyphenol known to activate sirtuins and mimic caloric restriction benefits. Coenzyme Q10: Essential for heart and energy metabolism, particularly in aging populations. Curcumin: A potent anti-inflammatory and antioxidant compound from turmeric. Vitamin D & B12: Crucial for immune modulation, neurocognitive health, and metabolic balance. This formulation represents a shift toward systems-level thinking in supplementation—where the goal is not to overload the body with isolated nutrients, but to restore harmony at the molecular level. Patent-Pending, Performance-Driven Longevity+™ is currently under patent review for its novel combination and delivery mechanism, with BioAro leveraging its proprietary research in nutrient absorption optimization and bioavailability. Clinical pilot studies are in planning phases across Canada and the UAE, with an emphasis on biomarker tracking to validate outcomes in real-world populations. Redefining the Future of Aging With its entrance into the longevity supplement space, BioAro is not planning to just sell supplements, it is shaping a new narrative around aging, one where prevention and performance intersect, and where scientifically grounded strategies replace fragmented wellness advice. "We envision a future where individuals manage aging proactively, backed by data, precision, and powerful science," adds Dr. Kapoor. "Longevity+ is just the beginning." About BioAroBioAro Inc. is a Canadian biotechnology and precision health company focused on multi-omics, AI-driven diagnostics, and preventive medicine. With a presence across Canada, USA, GCC, South America, EU, and UK, BioAro is a pioneer in integrating genomics, wearable technology, and personalized therapeutics into everyday healthcare solutions. Exclusive Offer! As part of our commitment to advancing personalized wellness, BioAro is offering an exclusive discount on our premium longevity supplements for users who download the app Biongevity Playstore and Apple store or visit our website at Start your journey to better health today! For media inquiries, distribution partnerships, or product samples, contact:Media Contact:MohiniEmail: info@ +1-403-250-2221 For more info, please visit: | Longevity+™ is a trademark of BioAro Inc. Patent pending. These statements have not been evaluated by regulatory bodies in all jurisdictions. This product is not intended to diagnose, treat, cure, or prevent any disease. Photos accompanying this announcement are available at: in to access your portfolio
Yahoo
25-06-2025
- Business
- Yahoo
Cosmos Health enters U.S. market with DolCas Biotech agreement
Cosmos Health (COSM) announced its entry into the U.S. market and the launch of U.S.-based manufacturing through a strategic agreement with DolCas Biotech LLC, a New Jersey-based developer and manufacturer of clinically studied nutraceutical ingredients. Cosmos Health is set to commence production in the United States at GMP-certified facilities, marking a significant milestone in the company's operational expansion. This move not only mitigates tariff exposure and cross-border logistical risks but also enhances production control beyond its existing European footprint, positioning Cosmos to scale efficiently in the global healthcare market, Cosmos Health said in a statement. Greg Siokas, CEO of Cosmos Health, stated: 'We are proud to reach this important milestone as we commence production in the United States through our agreement with DolCas Biotech, a partner widely recognized for its commitment to quality and innovation. This strategic move strengthens our supply chain, enhances production oversight, and positions Cosmos for scalable global growth. It also reduces exposure to tariff-related risks, adding resilience amid shifting trade dynamics.' Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on COSM: Disclaimer & DisclosureReport an Issue Cosmos Health reports Q1 EPS (3c) vs. (11c) last year Cosmos Health receives additional 180-cay compliance period from Nasdaq Sign in to access your portfolio
Associated Press
28-05-2025
- Business
- Associated Press
Stemtech Launches "StemPets(TM)" - the All-Natural Longevity Nutraceuticals Developed for Pets
Now Available for purchase in the U.S. Starting June 2025; Launching in Mexico Two Weeks Later NAPLES, FL / ACCESS Newswire / May 28, 2025 / Stemtech Corporation (OTCQB:STEK), the global leader in Human stem cell nutrition science and nutraceutical innovation, proudly announces the launch of StemPets™, Our newest breakthrough product designed exclusively for pets. Commencing June 2025, pet owners in the United States will be able to order this revolutionary new supplement, with availability in Mexico launching shortly after. Made with 100% plant-based, natural ingredients, StemPets™ is a first-of-its-kind anti-aging and longevity formula for dogs and cats. 'This great new product will provide anti-aging and longevity for our four-legged furry family members*,' said John W. Meyer, President and COO of Stemtech. 'Just add it onto their regular food as directed, and you'll begin to notice benefits like increased energy levels, a shinier coat, healthier skin, better digestion, and improved joint health'. Built on nearly two decades of innovation and success with human products like StemRelease3™, StemFlo® Advanced, and MigraStem®, StemPets™ represents the company's natural expansion into the booming pet wellness market. A Multi-Billion Dollar Opportunity The overall pet care industry is projected to surpass $500 billion globally by 2030, driven by increasing pet personal care and animal health awareness (source: Morgan Stanley, 2023). 'StemPets™ taps into currently one of the most explosive growth sectors in health and wellness,' added Meyer. 'As more consumers prioritize longevity for themselves, it's only natural they want the same for their family pets.' The star ingredient in StemPets™ is 'anacardic acid', a powerful all-natural compound registered with the Association of American Feed Control Officials (AAFCO). Stemtech holds exclusive distribution rights with its supplier, ensuring a competitive edge and unmatched quality in this category. StemPets™ is more than just a new product - it's a gateway into a high-margin, fast-scaling sector. With pet families seeking preventative, natural solutions for pet health, Stemtech is positioned as a first mover in the pet longevity and stem cell supplement sector. StemPets™ expands not just the product line, but the company's revenue potential. With international availability, a loyal customer base, and unmatched expertise in cellular health, Stemtech is building momentum across two powerhouse industries-anti-aging and pet care. *( Cats, dogs or any animal) ABOUT STEMTECH CORPORATION Stemtech Corporation, a leading stemceutical™ company with a direct sales distribution model, was founded on April 18, 2018, after acquiring the operations from its predecessor Stemtech International, Inc., which was established in 2005. From 2010 through 2015, Stemtech International, Inc., was recognized four separate times on the Inc. 5000 Fastest-Growing Companies list. In 2018, Stemtech underwent an extensive executive reorganization, and continued operations under new leadership as Stemtech Corporation. In August 2021, Stemtech became a publicly traded company (STEK) and has expanded business opportunities for its Independent Business Partners (IBPs), who may earn incomes by sharing Stemtech products. Stemtech is well positioned as the pioneer in stem cell nutrition, oral, skin care and soon pet health products, to increase sales in the wellness industry. Stemtech's comprehensive product portfolio reflects its dedication to optimal health. Our all-natural innovations like stemrelease3™ (release of the adult stem cells from the bone marrow), StemFlo™ Advanced (circulation of the stem cells through the bloodstream), MigraStem® (migration from the blood stream into the area need support), and OraStem® Toothpaste (whitening teeth, freshening breath, anti-microbial, promoting good gum health) demonstrate the company's unwavering commitment to quality-of-life products and natural effectiveness. The recent launch of Cellect One® Shield: HOCL-a multipurpose mist for skin care, cleaning, and disinfecting-and its integration with the Cellect One® Rapid Renew Stem Cell Peptide Night Cream (featuring the patented QXP ingredient) underscore Stemtech's innovative edge in the beauty, health and wellness industry. Stemtech is set to break new ground with the June 2025 debut of StemPets™ - a nutritional supplement designed for both dogs and cats. Tapping into the booming global pet wellness market, currently valued at over $303 billion annually, Stemtech is poised to transform pet health, with early adopters reporting remarkable improvements in health, energy, mood, and skin and hair quality for their furry family members. For nearly 20 years, Stemtech has not only championed the benefits of natural, plant-based ingredients but has also led the way in scientific innovation within the wellness, anti-aging, and longevity sectors. As industry forecasts and studies from reputable sources like the Global Wellness Institute project unprecedented growth, Stemtech's unwavering commitment to quality and innovation ensures that they will remain at the forefront of this transformative journey-making everyone healthier, while slowing down the aging process naturally. FORWARD-LOOKING STATEMENTS This announcement contains forward-looking statements within the meaning of the 'safe harbor' provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, those identified by words such as 'believes,' 'will,' 'expects,' 'anticipates,' 'estimates,' 'intends,' 'plans,' 'targets,' 'projects' and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in these forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, the results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the impact of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, and other risks discussed from time to time in our filings with the Securities and Exchange Commission. We undertake no obligation to update any forward-looking statements, or any information contained in this press release or in other public disclosures, at any time. Finally, the investing public is reminded that only announcements or information about Stemtech Corporation disseminated by the Company and bearing its name are considered official. For Investor Relations Information Contact: CEO Charles S. Arnold Phone: 336-918-0507 Email: [email protected] Stemtech Corporation Phone: +1 954-715-6000 ext 1040 Email: [email protected] References: Allied Market Research, 'Pet Supplements Market Size, Share & Trends Analysis Report by Pet Type, Application - Global Forecast 2023-2032" Morgan Stanley Research, 'Pet Industry Outlook: How the $500B Pet Economy Will Keep Growing' (2023) SOURCE: Stemtech Corporation press release
Yahoo
26-05-2025
- Business
- Yahoo
COSCIENS Biopharma Inc. Acknowledges Receipt of Intended Director Nominations from Goodwood for the Upcoming Annual and Special Meeting of Shareholders
TORONTO, ONTARIO, May 26, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) ('COSCIENS' or the 'Company'), a life sciences company developing and commercializing a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, today confirmed that its Board of Directors has received a letter from Goodwood Fund and Puccetti Funds Management Inc.('Goodwood') regarding six (6) director nominations for the Company's upcoming Annual and Special Meeting of Shareholders. 'We respectfully acknowledge receipt of the statement regarding the intentions from Goodwood and are carefully reviewing its contents,' said Ronnie Miller, Chair of the Board of COSCIENS Biopharma. 'With this in hand, the Board will evaluate and determine its path forward and remains fully committed to acting in the best interests of COSCIENS and our shareholders.' The Company will continue to provide updates to shareholders related to this COSCIENS Biopharma is a life sciences company which develops and commercializes a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products. Our technology includes proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources currently used in cosmeceutical products (i.e., oat beta glucan and avenanthramides which are found in leading skincare product brands like Aveeno and Burt's Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals. Our consolidated portfolio also includes macimorelin (Macrilen®; Ghryvelin®), the first and only U.S. FDA and European Medicines Agency approved oral test indicated for the diagnosis of adult growth hormone deficiency ('AGHD'). The company is listed on the NASDAQ Capital Market and the Toronto Stock Exchange, and trades on both exchanges under the ticker symbol "CSCI". For more information, please visit COSCIENS' website at Forward-Looking Statements Certain statements in this news release, referred to herein as "forward-looking statements", constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended, and "forward-looking information" under the provisions of Canadian securities laws. All statements, other than statements of historical fact, that address circumstances, events, activities, or developments that could or may or will occur are forward-looking statements. When used in this news release, words such as "anticipate", "assume", "believe", "could", "expect", "forecast", "future", "goal", "guidance", "intend", "likely", "may", "would" or the negative or comparable terminology as well as terms usually used in the future and the conditional are generally intended to identify forward-looking statements, although not all forward-looking statements include such words. Forward-looking statements in this news release include, but are not limited to, statements relating to: our plans for the Phase 2a Clinical Efficacy Study of its Avenanthramides tablets, our goal to commercialize our nutraceutical products (including our OBG chewable bar and YBG powder), the potential of our PGX technology and our goals and expectations regarding our other plans related to the development, manufacture or commercialization of our products. Forward-looking statements are necessarily based upon a number of factors and assumptions that, while considered reasonable by the Company as of the date of such statements, are inherently subject to significant business, economic, operational and other risks, uncertainties, contingencies and other factors, including those described below, which could cause actual results, performance or achievements of the combined Company to be materially different from results, performance or achievements expressed or implied by such forward-looking statements and, as such, undue reliance must not be placed on them. Forward-looking statements involve known and unknown risks and uncertainties which include, among others: the combined Company's present and future business strategies; operations and performance within expected ranges; anticipated future cash flows; local and global economic conditions and the environment in which the combined Company operates; anticipated capital and operating costs; uncertainty in our revenue generation from our marketed products, product development and related clinical trials and validation studies; results from our products under development may not be successful or may not support advancing the product; the failure of the DETECT-trial to achieve its primary endpoint in children (CGHD) may impact the market for macimorelin (Macrilen®; Ghryvelin®) in adults (AGHD) and the existing relationships we have for that product; ability to raise capital and obtain financing to continue our currently planned operations; our now heavy dependence on sales by and revenue from our main distributor of our legacy Ceapro products and its customers, the continued availability of funds and resources to successfully commercialize our products; the ability to secure strategic partners for late stage development, marketing, and distribution of our products; our ability to enter into out-licensing, development, manufacturing, marketing and distribution agreements with other pharmaceutical companies and keep such agreements in effect; our ability to protect and enforce our patent portfolio and intellectual property; and our ability to continue to list our common shares on the NASDAQ Capital Market. Investors should consult our quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties, including those discussed in our Annual Report on Form 20-F and MD&A filed under the Company's profile on SEDAR+ at and on EDGAR at We disclaim any obligation to update any such risks or uncertainties or to publicly announce any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a governmental authority or applicable law. No securities regulatory authority has either approved or disapproved of the contents of this news release. The Toronto Stock Exchange accepts no responsibility for the adequacy or accuracy of this news release. Issuer: Anna BiehnChief Executive OfficerE: ABiehn@ Investor Contact:Jenene ThomasJTC TeamT: (US): +1 (908) 824-0775E: csci@
Yahoo
23-05-2025
- Business
- Yahoo
Hair Growth Supplements Market to be Worth USD 2,581.1 Million by 2032: Coherent Market Insights
Coherent Market Insights Projects Global Hair Growth Supplements Market Size to Hit US$ 2,581.1 Mn by 2032, Expanding at 15.5% CAGR, Amid Growing Awareness of Hair Health Burlingame, CA, May 23, 2025 (GLOBE NEWSWIRE) -- The global hair growth supplements market was valued at approximately USD 940.1 million in 2025, and this figure is projected to reach around USD 2,581.1 million by 2032, expanding at a robust compound annual growth rate (CAGR) of 15.5%. The expansion of the hair growth supplements industry is largely driven by a growing preference for nutraceuticals over pharmaceuticals, due to their perceived higher safety profile. Additionally, rising awareness of the nutritional benefits provided by supplements has contributed to this shift. The increasing incidence of hair loss caused by various conditions, along with a heightened focus on maintaining healthy hair, has further boosted the demand for hair growth supplements. Request Sample Report @ Global Hair Growth Supplements Market Key Takeaways According to Coherent Market Insights (CMI), the global hair growth supplements market size is forecast to grow from USD 940.1 Mn in 2025 to USD 2,581.1 Mn by 2032. Global demand for hair growth supplements will likely increase at a robust CAGR of 15.5% throughout the assessment period. Based on product type, single ingredient supplements segment is expected to account for more than half of the global hair growth supplements market share in 2025. By formulation, capsules segment is projected to account for nearly one-fourth of the hair growth supplements market revenue share in 2025. In terms of functionality, hair regrowth segment is set to hold a prominent market share of more than 1/3 in 2025. North America is anticipated to dominate the global hair growth supplements industry, accounting for more than one-third of revenue share in 2025. As per Coherent Market Insights' latest hair growth supplements market analysis, Asia Pacific is expected to experience fastest growth during the assessment period. This can be attributed to growing health and wellness trend and increasing spending on hair supplements like vitamins. Rising emphasis on maintaining healthy hair has also fueled an adoption of hair growth supplements in the region. Also Read: Hair Loss Treatment Market Size, Share & Trend Analysis Report (2025-2032) Rising Prevalence of Hair Loss Disorders Propelling Growth Coherent Market Insights' latest hair growth supplements market research report outlines prominent factors driving industry growth. This includes increasing incidence of hair loss disorders globally. Hair loss disorders, such as androgenetic alopecia (AGA) and alopecia areata (AA) are becoming more prevalent globally. According to an article published by the American Academy of Dermatology (AAD), alopecia areata affects around 2% of the global population. This high disease burden is expected to boost growth of the hair growth supplements market. Hair growth supplements are gaining immense traction among individuals with hair loss issues. They have the tendency to help reduce hair fall and support growth of hair follicles. Thus, higher the cases of hair loss, greater will be demand for hair growth supplements. Side Effects and Availability of Alternative Therapies Limiting Market Growth The future hair growth supplements market outlook looks optimistic. However, factors like high cost of premium products and availability of alternative treatments are expected to limit market growth to some extent. Many hair growth supplements come with a heavy price tag. This limits their affordability and accessibility for a larger customer base, especially in low- and high-income regions. Availability of alternative hair loss treatments like PRPs, topical solutions, and hair transplants is also limiting the overall hair growth supplements market demand. Request a Customized Copy of the Report @ Growing Awareness of Hair Health Creating Growth Prospects for Players People across the world are becoming increasingly aware of the importance of maintaining healthy hair, mainly due to rising concerns about hair thinning and hair loss. This growing awareness is creating high demand for hair growth supplements. Modern consumers seek natural and scientifically backed solutions. This is expected to offer promising opportunities for hair growth supplement manufacturers and suppliers during the assessment period. Increasing geriatric population will also play a key role in boosting the hair growth supplements market growth. Aging often leads to hair thinning, prompting older consumers to seek non-invasive solutions like hair supplements. Emerging Hair Growth Supplements Market Trends Evolving beauty trends are acting as a catalyst for the growth of hair growth supplements market. Personal grooming and aesthetics are taking central stage in the modern world. More and more individuals are turning to hair growth supplements as a convenient and affordable way to address thinning hair and baldness. Social media is having a profound impact on the hair growth supplements industry. Leading wellness brands, celebrities, and influencers are increasingly promoting hair supplements on platforms like TikTok and Instagram. This growing visibility is increasing consumer interest as well as contributing to higher sales of hair growth supplements. Rising interest in preventive healthcare is significantly boosting hair growth supplements industry. Consumers are opting for hair supplements not only to address hair loss, but also as a proactive measure to maintain healthy hair as well as prevent future damage. There is also an increasing consumer preference for organic and plant-based hair growth supplements. This will create lucrative growth opportunities for hair growth supplement companies. Growing interest in personalized haircare is prompting companies to use advanced technologies like AI algorithms to create tailored treatments. For instance, Roots by Genetic Arts offers personalized topical hair growth solutions based on DNA analysis. Increasing popularity of DNA-based hair supplements will likely boost sales growth. Leading manufacturers of hair growth supplements are constantly innovating to stay ahead of the curve. For instance, they use marine collagen, adaptogens, and other functional ingredients in their products to woo customers. Similarly, they are strengthening their online presence to reach a wider audience. Another emerging trend in the hair growth supplements industry is the usage of sustainable packaging. Brands like Herbalife Nutrition Ltd. are transitioning toward compostable packaging for their hair wellness supplements. Also Read: Hair Care Products Market Size, Share & Trend Analysis Report (2025-2032) Analyst's View said senior analyst Ghanshyam Shrivastava. Current Events and Their Impact on the Hair Growth Supplements Market Event Description and Impact Rising Incidence of Hair Loss Disorders Description: Cases of hair loss disorders are increasing significantly due to factors like changing lifestyles, unhealthy eating habits, and increased stress levels. Impact: More people with hair loss issues will drive demand for hair growth supplements. Rising Health Consciousness and Wellness Trends Description: There is an increased focus on personal well-being and appearance globally. Impact: Rising emphasis on improving physical appearance will likely contribute to increasing hair growth supplements market value. Advancements in Hair Growth Research and Technology Description: Companies are striving to explore new active ingredients and formulations. Impact: Development of more effective hair growth supplements will further boost the target industry. Competitor Insights Key companies in hair growth supplements market report: Viviscal L'Oréal S.A. Nature's Bounty Country Life New Chapter Hairfinity Advanced Hair Care Biotin Beauty Nutrafol Swisse Wellness Parapharmacie Parapharmanet GNC Holdings Elvanveda Foshan Dezhong Pharmaceutical Herbalife Nutrition Ltd. Tianjin Tongrentang Group Key Developments In October 2024, Force Factor collaborated with Nutrition21, LLC to launch Hair Growth Accelerator. The new supplements are designed to support hair health, thickness, and growth. In October 2024, Nature's Bounty expanded its Women's wellness portfolio with the launch of new products, including Nature's Bounty Hair Growth Gummies, Nature's Bounty Intimacy Booster, and nature's Bounty Healthy pH Balance. These new products are formulated for stimulating hair growth, enhancing sexual health, and maintain vaginal pH balance in women. Buy this Premium Hair Growth Supplements Research Report | Fast Delivery Available - [130+ Pages] @ Market Segmentation By Product Type Insights (Revenue, USD Mn, 2020 - 2032) Single Ingredient Supplements Multi Ingredient Supplements By Formulation Insights (Revenue, USD Mn, 2020 - 2032) Capsules Gummies Tablets Powders Softgels By Functionality Insights (Revenue, USD Mn, 2020 - 2032) Hair Re-growth Hair Thinning Hair Fall Dandruff By Distribution Channel Insights (Revenue, USD Mn, 2020 - 2032) Offline Hypermarkets/Supermarkets Specialty Stores Convenience Stores Departmental Stores Drug Stores & Pharmacies Health & Wellness Stores Online E-commerce Others By End User Insights (Revenue, USD Mn, 2020 - 2032) Men Women Children Regional Insights (Revenue, USD Mn, 2020 - 2032) North America U.S. Canada Latin America Brazil Argentina Mexico Rest of Latin America Europe Germany U.K. Spain France Italy Russia Rest of Europe Asia Pacific China India Japan Australia South Korea ASEAN Rest of Asia Pacific Middle East GCC Countries Israel Rest of Middle East Africa South Africa North Africa Central Africa Also Read: Professional Hair Care Market Size, Share & Growth Analysis Report (2025-2032) Our Trusted Partners:Worldwide Market Reports, Coherent MI, Stratagem Market Insights Get Recent News: About Us: Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries. For Latest Update Follow Us:LinkedIn | Facebook | TwitterSign in to access your portfolio
